- Home
- PRTA vs REPL Comparison
PRTA vs REPL Comparison
Compare PRTA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- REPL
- Stock Information
- Founded
- PRTA 2012
- REPL 2015
- Country
- PRTA Ireland
- REPL United States
- Employees
- PRTA N/A
- REPL N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- PRTA Health Care
- REPL Health Care
- Exchange
- PRTA Nasdaq
- REPL Nasdaq
- Market Cap
- PRTA 802.8M
- REPL 816.4M
- IPO Year
- PRTA N/A
- REPL 2018
- Fundamental
- Price
- PRTA $14.01
- REPL $10.80
- Analyst Decision
- PRTA Buy
- REPL Strong Buy
- Analyst Count
- PRTA 7
- REPL 4
- Target Price
- PRTA $57.67
- REPL $17.00
- AVG Volume (30 Days)
- PRTA 476.3K
- REPL 432.6K
- Earning Date
- PRTA 11-12-2024
- REPL 11-12-2024
- Dividend Yield
- PRTA N/A
- REPL N/A
- EPS Growth
- PRTA N/A
- REPL N/A
- EPS
- PRTA N/A
- REPL N/A
- Revenue
- PRTA $133,350,000.00
- REPL N/A
- Revenue This Year
- PRTA $60.63
- REPL N/A
- Revenue Next Year
- PRTA N/A
- REPL $469.74
- P/E Ratio
- PRTA N/A
- REPL N/A
- Revenue Growth
- PRTA N/A
- REPL N/A
- 52 Week Low
- PRTA $14.00
- REPL $4.92
- 52 Week High
- PRTA $41.55
- REPL $12.97
- Technical
- Relative Strength Index (RSI)
- PRTA 31.91
- REPL 38.50
- Support Level
- PRTA $17.27
- REPL $11.45
- Resistance Level
- PRTA $18.60
- REPL $12.73
- Average True Range (ATR)
- PRTA 1.11
- REPL 0.69
- MACD
- PRTA -0.15
- REPL -0.16
- Stochastic Oscillator
- PRTA 0.20
- REPL 8.82
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.